Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2014, Article ID 712040, 2 pages
http://dx.doi.org/10.1155/2014/712040
Case Report

Guillain-Barré Syndrome following Treatment with Sunitinib Malate

Department of Internal Medicine, Crittenton Hospital Medical Center, Wayne State University, Rochester, MI 48307, USA

Received 30 January 2014; Accepted 9 May 2014; Published 11 June 2014

Academic Editor: Sercan Aksoy

Copyright © 2014 Ziad Kanaan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. R. Adams and M. Leggas, “Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors,” Clinical Therapeutics, vol. 29, no. 7, pp. 1338–1353, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. Administration UFaD, FDA Approves New Treatment for Gastrointestinal and Kidney Cancer, 2006.
  3. B. Mulherin, N. K. Loconte, and K. D. Holen, “Guillain-Barré syndrome after treatment with sunitinib malate?” Oncology, vol. 22, no. 1, pp. 66–67, 70–71, 2008. View at Google Scholar · View at Scopus
  4. E. Beşkonakli, F. Ak, I. Solaroǧlu, and Ö. Okutan, “The Guillain-Barre syndrome after lumbar disc surgery: a case report,” Turkish Neurosurgery, vol. 14, no. 3-4, pp. 109–111, 2004. View at Google Scholar · View at Scopus
  5. C. A. Naranjo, U. Busto, and E. M. Sellers, “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, no. 2, pp. 239–245, 1981. View at Google Scholar · View at Scopus
  6. G. Martín, L. Bellido, and J. J. Cruz, “Reversible posterior leukoencephalopathy syndrome induced by sunitinib,” Journal of Clinical Oncology, vol. 25, no. 23, p. 3559, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Ansari and M. K. George, “Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report,” Journal of Medical Case Reports, vol. 7, article 54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Aparicio-Gallego, M. Blanco, A. Figueroa et al., “New insights into molecular mechanisms of sunitinib-associated side effects,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2215–2223, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. O. Watanabe, I. Maruyama, K. Arimura et al., “Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome,” Muscle & Nerve, vol. 21, no. 11, pp. 1390–1397, 1998. View at Google Scholar
  10. K. Sakai, K. Komai, D. Yanase, and M. Yamada, “Plasma VEGF as a marker for the diagnosis and treatment of vasculitic neuropathy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 2, article 296, 2005. View at Publisher · View at Google Scholar · View at Scopus